ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
Condition(s):Hodgkin LymphomaLast Updated:May 10, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Hodgkin LymphomaLast Updated:May 10, 2023Active, not recruiting
Condition(s):Renal Cell Cancer Metastatic; Non-small Cell Lung Cancer Metastatic; Pleural Effusion, MalignantLast Updated:March 8, 2023Completed
Condition(s):Oral Cavity Squamous Cell CarcinomaLast Updated:October 8, 2021Unknown status
Condition(s):High Grade Glioma; Brain CancerLast Updated:December 14, 2021Completed
Condition(s):Hodgkin LymphomaLast Updated:December 5, 2023Completed
Condition(s):Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Male Urogenital Diseases; Urinary Bladder Neoplasm; Antineoplastics ToxicityLast Updated:February 29, 2024Recruiting
Condition(s):Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myelodysplastic Syndrome Acute Myeloid LeukemiaLast Updated:December 5, 2023Withdrawn
Condition(s):Refractory Central Nervous System Lymphoma; Relapsed Primary Central Nervous System Lymphoma; Primary Central Nervous System LymphomaLast Updated:July 7, 2022Active, not recruiting
Condition(s):Squamous Cell Carcinoma of Head and NeckLast Updated:April 6, 2023Completed
Condition(s):Bladder CancerLast Updated:November 8, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.